Kronos Bio (KRON) has filed to raise $175 million in an IPO of its common stock, according to an S-1 registration statement.
The company is a clinical stage biopharma advancing treatment candidates for various cancer conditions.
KRON has produced intriguing Phase 1b/2 trial results for its lead candidate and has a significant collaboration relationship with Gilead.
For life science investors with a hold time frame of 24 to 36 months, the IPO may be worth consideration.
Company & Technology
San Mateo, California-based Kronos was founded to develop inhibitor treatments for acute myeloid leukemia and MYC-amplified solid tumors.
Management is headed by president and CEO Mr. Norbert Bischofberger, Ph.D., who has been with the firm since April 2018 and was previously EVP, Research & Development and Chief Scientific Officer at Gilead Sciences (GILD).
Below is a brief overview video of the causes and symptoms of acute myeloid leukemia [AML]: